Dianthus Therapeutics, Inc. (DNTH) Stock

Dianthus Therapeutics, Inc. (DNTH) is a Healthcare stock trading at $82.47 (as of 2026-06-18), with a market capitalization of $5.08B and a trailing P/E of -19.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Valuation — source: SEC EDGAR (first-party)
Price$82.47
Market Cap$5.08B
P/E Ratio-19.4
EV / EBITDA-20.2
Price / Book3.73
Price / Sales757.85
DCF Value (model)$-48.25
DCF Upside vs Price-158.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.04M
Net Margin-7973.3%
Return on Equity-14.5%
Current Ratio29.25
Revenue Growth (YoY)-67.3%
EPS Growth (YoY)64.7%
Financial Health — source: SEC EDGAR
Altman Z-Score57.51 (safe)
Valuation vs Sector & Industry
Stock P/E-19.4
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-192.6%
vs Industry-212.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($651.86M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Sionna Therapeutics, Inc. (SION)
  • Syndax Pharmaceuticals, Inc. (SNDX)
  • Harrow Health, Inc. (HROW)
  • Pharvaris N.V. (PHVS)
  • Nurix Therapeutics, Inc. (NRIX)
  • ANI Pharmaceuticals, Inc. (ANIP)
  • MannKind Corporation (MNKD)
  • Kodiak Sciences Inc. (KOD)
DNTH earnings history · DNTH institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.